AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16913429 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected impact (10.1 m/s2)
Number of subjects: 29
Study 16913429 — intervention group
Group type: COMPARATOR
Intervention: Impact awareness (all impacts)
Number of subjects: 29
Study 16913429 — intervention group
Group type: COMPARATOR
Intervention: Timing of masticatory muscle response
Number of subjects: 29
Study 15497711 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 32
Study 11379842 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 113
Study 11379842 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine monotherapy
Number of subjects: 113
Study 9416380 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified heparin dosing nomogram (institution-specific)
Number of subjects: 0
Study 9416380 — intervention group
Group type: COMPARATOR
Intervention: Physician-directed dosing
Number of subjects: 0
Study 9416380 — intervention group
Group type: COMPARATOR
Intervention: Unmodified heparin dosing nomogram (18 units/kg/h)
Number of subjects: 0
Study 8311278 — intervention group
Group type: EXPERIMENTAL
Intervention: S (+) ketamine (1 mg/kg, Group I, n = 30)
Number of subjects: 60
Study 8311278 — intervention group
Group type: COMPARATOR
Intervention: Racemic ketamine (2 mg/kg, Group II, n = 30)
Number of subjects: 60
Study 3276360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 179
Study 3276360 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 179
Study 31286658 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 16
Study 31286658 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 16
Study 28453453 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) for 25 minutes per session, two sessions per week for 4 months
Number of subjects: 85
Study 28453453 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic therapy for 50 minutes per session, two sessions per week for 4 months
Number of subjects: 85
Study 28453453 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological treatment alone (control group)
Number of subjects: 85
Study 26775369 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound
Number of subjects: 90
Study 26775369 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound
Number of subjects: 90
Study 26775369 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound
Number of subjects: 90
Study 23182407 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg pramipexole
Number of subjects: 0
Study 23182407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21196428 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) for 30 minutes before and throughout heel stick
Number of subjects: 28
Study 18458518 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated symptom management program for 6 months (tailored education, stress management, exercise, diet, deep breathing, music therapy, periodical telephone monitoring, daily log)
Number of subjects: 58
Study 18458518 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated symptom management program for 6 months
Number of subjects: 58
Study 18458518 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study 16569351 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin (15 mg aerosolized, twice daily for 10 days)
Number of subjects: 311
Study 16569351 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin/clavulanate (50 mg/Kg, twice daily for 10 days)
Number of subjects: 311
Study 12660683 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 2 mg
Number of subjects: 218
Study 12660683 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 4 mg
Number of subjects: 218
Study 12660683 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 218
Study 12660683 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 218
Study 12660683 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (all doses)
Number of subjects: 218
Study 12660683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 10913038 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (T)
Number of subjects: 16
Study 10913038 — intervention group
Group type: COMPARATOR
Intervention: Sedentary (S)
Number of subjects: 16
Study 9014623 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone (group M)
Number of subjects: 42
Study 9014623 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group P)
Number of subjects: 42
Study 1395889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of aminophylline slowly
Number of subjects: 80
Study 1395889 — intervention group
Group type: COMPARATOR
Intervention: Traditional three drugs combination treatment
Number of subjects: 80
Study 1395889 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group A and B
Number of subjects: 80
Study 3887851 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 50
Study 3887851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 29567846 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led continuity model (intervention clinics)
Number of subjects: 39
Study 29567846 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 39
Study 26740634 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop insulin delivery
Number of subjects: 12
Study 24905629 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine/caffeine combination (200/20 mg, n=6)
Number of subjects: 13
Study 24905629 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=7)
Number of subjects: 13
Study 22301417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) twice daily after a 14-day once-daily lead-in period
Number of subjects: 359
Study 19952998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injections
Number of subjects: 125
Study 17106838 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital detoxification treatment
Number of subjects: 0
Study 17106838 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study 15704504 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibition tape
Number of subjects: 30
Study 15704504 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation tape
Number of subjects: 30
Study 15704504 — intervention group
Group type: COMPARATOR
Intervention: No tape
Number of subjects: 30
Study 12218740 — intervention group
Group type: EXPERIMENTAL
Intervention: Long bout (one 30-min walk per day, 5 days/week)
Number of subjects: 21
Study 12218740 — intervention group
Group type: EXPERIMENTAL
Intervention: Short bouts (three 10-min walks per day, 5 days/week)
Number of subjects: 21
Study 12218740 — intervention group
Group type: COMPARATOR
Intervention: Control (not explicitly mentioned)
Number of subjects: 21
Study 10086941 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (200 microg or one puff twice daily)
Number of subjects: 49
Study 10086941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10086941 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 49
Study 7885808 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus distribution including water in the stimulus set (Experiments 1-3)
Number of subjects: 0
Study 7885808 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of subjective ranges of two taste qualities (Experiment 4)
Number of subjects: 0
Study 7885808 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation of expected response distribution (Experiments 5-6)
Number of subjects: 0
Study 2236711 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg bupivacaine 0.5%
Number of subjects: 60
Study 2236711 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 ml bupivacaine 0.25%
Number of subjects: 60
Study 2236711 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml bupivacaine 0.175%
Number of subjects: 60
Study 1266755 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy
Number of subjects: 150
Study 1266755 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy
Number of subjects: 150
Study 31355770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand scaling followed by glycine powder air polishing (GPAP)
Number of subjects: 50
Study 31355770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling followed by glycine powder air polishing (GPAP)
Number of subjects: 50
Study 31355770 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand scaling alone
Number of subjects: 50
Study 31355770 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scaling alone
Number of subjects: 50
Study 31355770 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 50
Study 28795506 — intervention group
Group type: EXPERIMENTAL
Intervention: D-4F 300 mg
Number of subjects: 62
Study 28795506 — intervention group
Group type: EXPERIMENTAL
Intervention: D-4F 500 mg
Number of subjects: 62
Study 28795506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 25441237 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed multicomponent exercise program
Number of subjects: 401
Study 25441237 — intervention group
Group type: COMPARATOR
Intervention: Nutrition control program
Number of subjects: 401
Study 24315327 — intervention group
Group type: EXPERIMENTAL
Intervention: Value of Information (VoI) analysis
Number of subjects: 0
Study 24315327 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis (DA)
Number of subjects: 0
Study 24315327 — intervention group
Group type: EXPERIMENTAL
Intervention: Further research
Number of subjects: 0
Study 21378155 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg daily
Number of subjects: 70
Study 21378155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 19382472 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy with Chinese drugs (HT‐C)
Number of subjects: 100
Study 19382472 — intervention group
Group type: COMPARATOR
Intervention: Conventional functional training
Number of subjects: 100
Study 17365264 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 0
Study 17365264 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (either dosage)
Number of subjects: 0
Study 17365264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15479320 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon anaesthesia (Xe, n = 20)
Number of subjects: 39
Study 15479320 — intervention group
Group type: COMPARATOR
Intervention: Total intravenous anaesthesia (TIVA, n = 19)
Number of subjects: 39
Study 11583193 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 on days 1 + 8 of a three-week schedule combined with carboplatin AUC 4 on day 1
Number of subjects: 26
Study 11583193 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin alone (control group in a future randomized trial)
Number of subjects: 26
Study 9676348 — intervention group
Group type: EXPERIMENTAL
Intervention: Batch at the lower in vitro specification range
Number of subjects: 18
Study 9676348 — intervention group
Group type: EXPERIMENTAL
Intervention: Batch at the upper in vitro specification range
Number of subjects: 18
Study 9676348 — intervention group
Group type: COMPARATOR
Intervention: Batch in the middle of the in vitro specification range
Number of subjects: 18
Study 7933396 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 20
Study 7933396 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine
Number of subjects: 20
Study 2894780 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 9
Study 2894780 — intervention group
Group type: COMPARATOR
Intervention: Trihexyphenidyl
Number of subjects: 9
Study 30486656 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention combining cognitive stimulation group and tai chi (14 sessions, twice a week)
Number of subjects: 80
Study 30486656 — intervention group
Group type: COMPARATOR
Intervention: Treat as usual
Number of subjects: 80
Study 29453687 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg
Number of subjects: 44
Study 29453687 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 44
Study 29453687 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60 mg
Number of subjects: 44
Study 29453687 — intervention group
Group type: COMPARATOR
Intervention: Boosted ARTs
Number of subjects: 44
Study 27167637 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (PC) integrated with standard oncology care (SC)
Number of subjects: 151
Study 27167637 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (PC)
Number of subjects: 151
Study 27167637 — intervention group
Group type: COMPARATOR
Intervention: Standard oncology care (SC)
Number of subjects: 151
Study 24625936 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine plus pralidoxime
Number of subjects: 120
Study 24625936 — intervention group
Group type: COMPARATOR
Intervention: Atropine alone
Number of subjects: 120
Study 23375824 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-unit media education program including one unit on gambling, implemented by trained teachers during class time.
Number of subjects: 2109
Study 23375824 — intervention group
Group type: COMPARATOR
Intervention: Regular classes without any specific intervention (control group).
Number of subjects: 2109
Study 20636656 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (social network trial)
Number of subjects: 950
Study 20636656 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched case-control study)
Number of subjects: 950
Study 20636656 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-incarceration behaviors
Number of subjects: 950
Study 18268065 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) + L-arginine (ARG)
Number of subjects: 24
Study 15901520 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom failure
Number of subjects: 921
Study 12460699 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 15 mg/day)
Number of subjects: 309
Study 12460699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (10 to 30 mg/day)
Number of subjects: 309
Study 12460699 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Fosinopril (5/10 to 15/30 mg/day)
Number of subjects: 309
Study 12460699 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 309
Study 10554808 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte‐CSF (G‐CSF) + Erythropoietin (EPO)
Number of subjects: 52
Study 10554808 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ringed sideroblastic anaemia (RARS)
Number of subjects: 52
Study 10554808 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 5q -
Number of subjects: 52
Study 10554808 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high transfusion need
Number of subjects: 52
Study 10554808 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with refractory anaemia with an excess of blasts (RAEB)
Number of subjects: 52
Study 10554808 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RARS and thrombocytosis who normalized their platelet counts
Number of subjects: 52
Study 10554808 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study 8533910 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg oral famotidine 3 h before induction of anesthesia
Number of subjects: 30
Study 8533910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1758322 — intervention group
Group type: EXPERIMENTAL
Intervention: Group teaching in problem-based interviewing with video and audiotape feedback
Number of subjects: 0
Study 1758322 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching their own consultations in a group feedback setting
Number of subjects: 0
Study 1758322 — intervention group
Group type: COMPARATOR
Intervention: Video feedback of tutorial sessions
Number of subjects: 0
Study 1758322 — intervention group
Group type: COMPARATOR
Intervention: Discussion about how to teach
Number of subjects: 0
Study 1758322 — intervention group
Group type: COMPARATOR
Intervention: No further teaching
Number of subjects: 0
Study 7036291 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunostimulation (BCG or levamisole) with chemotherapy dimethyl ‐ triazeno ‐ imidazole ‐ carboxamide (DTIC)
Number of subjects: 0
Study 7036291 — intervention group
Group type: EXPERIMENTAL
Intervention: New agents being screened for stage III melanoma
Number of subjects: 0
Study 31780869 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF MMP-8 concentration above the median
Number of subjects: 245
Study 30566485 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition 2 - recommended (theory-based) information correction
Number of subjects: 243
Study 30566485 — intervention group
Group type: COMPARATOR
Intervention: Condition 1 - common information correction
Number of subjects: 243
Study 26363307 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined peer and parent intervention (n=342)
Number of subjects: 680
Study 26363307 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control (n=338)
Number of subjects: 680
Study 25083802 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care (LG‐CC)
Number of subjects: 304
Study 25083802 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 304
Study 22116797 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern draisine
Number of subjects: 21
Study 22116797 — intervention group
Group type: COMPARATOR
Intervention: Rollator
Number of subjects: 21
Study 22116797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both walking aids
Number of subjects: 21
Study 21055597 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored maxillary protraction (BAMP)
Number of subjects: 21
Study 21055597 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated Class III subjects)
Number of subjects: 21
Study 17682590 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational games
Number of subjects: 34
Study 17682590 — intervention group
Group type: COMPARATOR
Intervention: Standard education techniques (Control)
Number of subjects: 34
Study 17557470 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 37
Study 17557470 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 37
Study 17557470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 12594140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine + clonidine
Number of subjects: 45
Study 12594140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 45
Study 12594140 — intervention group
Group type: COMPARATOR
Intervention: i.v. morphine (control group)
Number of subjects: 45
Study 11012468 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 1960
Study 11012468 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 1960
Study 11012468 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 1960
Study 8816618 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a)
Number of subjects: 100
Study 8816618 — intervention group
Group type: COMPARATOR
Intervention: No GnRH agonist (control group A)
Number of subjects: 100
Study 1609047 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1-3 mg daily)
Number of subjects: 68
Study 1609047 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine (25-75 mg daily)
Number of subjects: 68
Study 6388341 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded brackets and eyelets
Number of subjects: 2
Study 6388341 — intervention group
Group type: COMPARATOR
Intervention: Control group (bonded contralaterally and at random)
Number of subjects: 2
Study 29998861 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser ablation
Number of subjects: 32
Study 29998861 — intervention group
Group type: COMPARATOR
Intervention: Motorized dermabrasion
Number of subjects: 32
Study 30251639 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial resuscitation with FiO2 0.21
Number of subjects: 240
Study 30251639 — intervention group
Group type: COMPARATOR
Intervention: Initial resuscitation with FiO2 1.0
Number of subjects: 240
Study 30251639 — intervention group
Group type: EXPERIMENTAL
Intervention: FiO2 0.21
Number of subjects: 240
Study 30251639 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-minute blood oxygen saturation (SpO2) <80%
Number of subjects: 240
Study 27068684 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Start‐Départ Santé intervention
Number of subjects: 61
Study 23348662 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity exercise intervention using virtual-reality (Nintendo Wii Fit Plus)
Number of subjects: 7
Study 22553044 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST (Fast Alcohol Screening Test)
Number of subjects: 205
Study 22553044 — intervention group
Group type: EXPERIMENTAL
Intervention: M-SASQ (modified version of the Single Alcohol Screening Question)
Number of subjects: 205
Study 22553044 — intervention group
Group type: COMPARATOR
Intervention: AUDIT (Alcohol Use Disorders Identification Test)
Number of subjects: 205
Study 22553044 — intervention group
Group type: EXPERIMENTAL
Intervention: Probation setting
Number of subjects: 205
Study 22553044 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 205
Study 22553044 — intervention group
Group type: COMPARATOR
Intervention: Violent offences
Number of subjects: 205
Study 22553044 — intervention group
Group type: COMPARATOR
Intervention: Property offences
Number of subjects: 205
Study 21055649 — intervention group
Group type: EXPERIMENTAL
Intervention: HFMS (Alere DayLink HF Monitoring System)
Number of subjects: 315
Study 21055649 — intervention group
Group type: COMPARATOR
Intervention: SC (Standard Care)
Number of subjects: 315